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The A/B domains of nuclear receptors such as thyroid receptor a (TRa)
are considered to be conformationally flexible and can potentially adopt
multiple structural conformations. We used intrinsic tryptophan fluores-
cence quenching and circular dichroism spectroscopy to characterize the
unfolding of this A/B domain upon DNA binding to the contiguous DNA-
binding domain (DBD). We propose that this allosteric change in A/B
domain conformation can allow it to make the multiple interactions with
distinct molecular factors of the transcriptional preinitiation complex. We
further suggest that by influencing the affinity of the DBD for DNA, A/B
domain can fine-tune the recognition of promotor DNA by TRa.
The effects of the thyroid hormone (triiodothyronine,
T3) are widespread in development, homeostasis and
metabolism. The T3 receptors (thyroid hormone recep-
tor, TR) are encoded by two closely related genes (a and
b) [1]. The T3Ra genes in humans express the T3-bind-
ing isoform TRa1 [2]. The TRb gene expresses TRb1
and TRb2, which differ only in their N-terminal A/B
regions, and are also distinct from the A/B region of
TRa1 [3]. TRa is mostly expressed in the brain [4] and is
associated with the development of the nervous system
[5]. TRa is constitutively localized within the nucleus
where it interacts with nucleosomal DNA [6,7]. In the
absence of T3 ligand, TRa is observed to actively repress
transcription through interactions with transcriptional
corepressors such as SMRT and NCoR [8–10].
Thyroid hormone receptors are members of the
nuclear receptor (NR) superfamily of ligand-mediated
transcription factors [2]. NRs have common modular
structural features that include an N-terminal domain
(A/B domain, Fig. 1A). This A/B domain is of vari-
able length and amino acid sequence and encompasses
a ligand-independent transactivation function (AF1)
domain that is critical for regulating transactivation
[11,12]. Following the A/B domain is a highly con-
served DNA-binding domain (DBD; C domain,
Fig. 1A) that binds palindromic DNA sequences called
hormone response elements (HRE). A short ‘hinge’
sequence (D domain) connects the DBD (C domain)
to a C-terminal ligand-binding domain (LBD; E/F
domain, Fig. 1A). Upon binding agonist-ligands, the
LBD (E/F domain) undergoes conformational changes
which results in the recruitment of coactivator mole-
cules [13–17]. Antagonists and inverse agonists disrupt
the ‘active-state’ LBD and the resulting LBD confor-
mation functions as a docking site for corepressors
[18–20]. Also, except for the A/B domains, the amino
acid sequences of TRa and TRb are over 90% identi-
cal. Since TRs differ most significantly in the N-
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terminal A/B domain, it is suggested that this region
plays a significant role in mediating the distinct roles
of these receptors [21]. It has also been proposed that
TRa-mediated transcriptional regulation can also
occur through specific interactions of the A/B domain
with the PIC, specifically with transcription factor IIB
(TFIIB) [21–24] and the TATA-binding protein (TBP)
[25]. Transcriptional repression and similar interactions
have also been observed between TRb and TFIIB
[21,23,26].
By and large, the N-terminal domain of NRs is the
least understood. This A/B region is diverse in size,
sequence and is conformationally malleable [12,27,28],
implying that this domain plays disparate roles in con-
ferring cell type and/or promoter specificity [21].
Moreover, there are no data on the atomic resolution
structure of any NR A/B domain conformation to
date.
Nuclear receptor structure is strongly affected by the
presence and even sequence of the DNA response ele-
ment [29]. The source of these may result from confor-
mational changes within the DBD as observed in
structures of glucocorticoid (GR) bound to multiple
GREs [30,31]. This may explain, in part, the DNA-
dependent interactions between the TRa DBD and
LBD (E/F domain) reported earlier [32]. DNA binding
is also central to allosteric communication between the
A/B and C (DBD) domains [27,33–36]. Multiple
DNA-binding site sequences have been identified for
TRa. TR isoforms and oligomers exhibit preferential
binding to specific DNA sequences called thyroid
response elements (TRE) [37]. These TRE sequences
consist of consensus AGGTCA (half-sites) arranged as
direct repeats (DR), palindromic sequences (Pal) or
inverted palindromic sequences (IP), each with differ-
ing spacing between the half-sites.
Allostery is a recognized regulatory feature within
NRs such that ligand binding and even minor pertur-
bations (such as nonbinding-site mutations) are
detected at distal regions of NRs [15–17,27,38–41].
With distinct structural changes, allostery has been
observed to link ligand, coactivator and the DNA-
binding sites [17,32,42]. Furthermore, DNA binding is
also central to allosteric communications between the
A/B and C (DBD) domains [27,33–36,43]. Increas-
ingly, cooperative interactions between multiple NR
Fig. 1. (A) NR domain topology displaying single-letter domain assignments. The region circled in green (above) is the focus of this study
and the structural topology shows the relative orientation of the domains with DR4 TRE DNA (below). (B) The amino acid sequence of the
TRa A/B + C domain molecular construct is colour coded (A/B domain in red and C domain in green). The single tryptophan is shown in
blue. (C and D) Results from the Escherichia coli overexpression and purification of the TRa (A/B + DBD) and TRa (DBD) molecular
constructs, respectively. The molecular weight standards are on lane 6 (the positions of the 75 kDa and 25 kDa standards are labelled) and
the purified proteins are in lane 7.
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domains have also been reported to modulate transac-
tivation suggesting additional layers of regulation
[32,44].
Here, we report a notable conformational change in
the TRa A/B domain that is initiated through allostery
through the TRa DBD by DNA. The shorter, 50-
amino acid A/B domain of TRa encompasses several
of the structural motifs that have been identified in
NRs with significantly larger A/B domains to be
important for ligand-independent activity [24]. Of
these, distinct variations of the KRKRK amino acid
sequence motif are common to several NRs including
TR, progesterone (PR) and the liver X receptor (LXR)
[28]. We are able to observe that the TRa A/B domain
can allosterically enhance the binding affinity of the
receptor for direct repeat 4 (DR4) TRE DNA. Fur-
thermore, using a combination of circular dichroism
(CD) and intrinsic tryptophan fluorescence spec-
troscopy, we can report that the binding of DNA to
the TRa DBD (C domain) induces unfolding within
the flanking TRa A/B domain. Overall, these observa-
tions suggest a structural basis for intramolecular
cooperativity within TRa that fine-tunes binding to
specific DNA sites.
Experimental procedures
Protein expression and purification
The chicken thyroid hormone receptor a1 gene (cTRa1,
NCBI accession #: NP_990644.1) is over 90% identical to
human TRa1 (NCBI accession #: NP_955366.1) at the
amino acid level and is used for all experiments here. TRa
(A/B + DBD, amino acid 1–154), TRa (DBD, amino acids
37–154) [32] and TRa (A/B domain, amino acids 1–50)
were cloned into the plasmid pET15b (Life Technologies
Inc., Carlsbad, CA, USA) to produce pET15b-TRa (A/
B + DBD), pET15b-TRa(DBD) and pET15b-TRa (A/B
domain), respectively. Proteins were produced in
Escherichia coli BL21 (DE3) RIPL cells. Protein synthesis
was induced with 0.5 mM isopropyl b-D-thiogalactoside
(IPTG) at 20ᵒC. Cells were lysed by sonication in 50 mM
Tris, pH 8.0, 500 mM NaCl, 20 mM Imidazole, 10% glyc-
erol, 1 protease inhibitor tablet, 5.7 mM b-mercaptoethanol,
0.5 lM PMSF, 10 lM ZnCl2, 10 mM MgCl2, recombinant
DNase 1 (10 U). 6XHis-tagged TR (A/B + DBD) and TR
(DBD) were purified using Ni-NTA agarose (Qiagen,
Germantown, MD, USA) with 0.3 M Imidazole, 50 mM
Tris, pH 8.0, 500 mM NaCl and 10% glycerol. Proteins
were further purified by size-exclusion chromatography
(SEC) using S200 Superdex 16/60 column (GE Healthcare
Life Sciences, Pittsburgh, PA, USA) in buffer consisting
50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), pH = 7.5 (at 25 ᵒC), 125 mM NaCl, 5 mM
MgCl2, 1 mM tris (2-carboxyethyl)phosphine hydrochloride;
TCEP). Protein was analysed using SDS/PAGE. Protein
concentration was determined using the Bradford Assay
(BioRad, Hercules, CA, USA).
Preparation of DR4 TRE DNA adduct
19-mer DNA oligos containing the thyroid hormone
response element (TRE) consensus site (DR4: 50-
CCAGGTCATTTCAGGTCAG-30, where the underlined
sequence is the NR binding site) were commercially
obtained (Life Technologies Inc.) as single-stranded oligo-
mers [45]. Double-stranded DR4 TRE was prepared by
mixing the complementary strands in equimolar ratios to a
final concentration of 2 mM, followed by heat denaturation
at 95 ᵒC for 5 min and annealing by gradual cooling to
room temperature.
Isothermal titration calorimetry (ITC)
Thyroid receptor a (A/B + DBD) and TRa (DBD), puri-
fied by SEC, were used for isothermal titration calorimetry
(ITC) measurements using VP-ITC MicroCalTM (MicroCal
Inc., Northampton, MA, USA). Protein and ligand were
prepared in 50 mM HEPES, pH 7.5, 125 mM NaCl, 5 mM
MgCl2 and 1 mM TCEP. For titration experiments, protein
concentration ranged from 30 to 45 lM and ligand DR4
TRE: 50-CCAGGTCATTTCAGGTCAG-30 concentration
ranged from 300 to 400 lM. Both protein and ligand were
degassed for 5–10 min. The experiments were initiated by
injecting 28 9 10 lL aliquots of DR4 TRE from the syr-
inge into the calorimetric cell containing 1.5 mL of protein
solution. All the titrations were performed at 25 °C and the
buffer (pH adjusted to 7.5 at 25 °C). The change in thermal
power as a function of each injection was automatically
recorded using MICROCAL ORIGIN software and the raw data
were further processed to yield binding isotherms of heat
released per injection as a function of molar ratio of DR4
TRE to TRa (A/B + DBD) or TRa (C domain). The
data were acquired and processed using the MICROCAL
ORIGIN (MicroCal Inc.) software. Data were collected in
triplicate.
Fluorescence spectroscopy
Fluorescence emission spectra of purified TRa (A/B +
DBD) in 50 mM HEPES, pH 7.5, 125 mM NaCl, 5 mM
MgCl2, 1 mM TCEP were recorded at various concentra-
tions of DR4 TRE. A total of 2 mL protein (2 lM) was used
to which 2 lL of DR4 TRE (0–9.4 lM) was added for each
scan. To monitor the effect of sample dilution due to DR4
TRE titrations into protein, equal volumes of buffer were
titrated into 2 mL protein (2 lM). The spectra were moni-
tored using a PerkinElmer-LS 55 Fluorescence Spectrometer
at excitation wavelength of 295 nm at 300 nmmin1.
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Emission wavelength range was set at 310 nm to 450 nm,
with slit width of 5.0 nm; 1 cm path length rectangular cuv-
ettes were used to take all measurements at room tempera-
ture. The final fluorescence intensity change curve was a
result of three averaged curves from individual experiments.
The contribution of DR4-TRE to the TRa (A/
B + DBD) + DR4 TRE spectrum was corrected by sub-
tracting the spectrum of TRa (A/B + DBD) + buffer. Since
multiple studies have shown that two molecules of TR bind
a single TRE DNA [32,46], titration data curves were fitted
to a two-site binding, nonlinear regression fitting model by
PRISM7 (GraphPad software, La Jolla, CA, USA, www.gra
phpad.com), where change in fluorescence intensity was
plotted against increasing concentrations of DR4 TRE rang-
ing from 0.0 lM to 9.4 lM (Fig. 1B.)
Circular dichroism (CD)
Circular dichroism spectra of TRa (A/B + DBD) and TRa
(DBD; in 50 mM sodium phosphate buffer, pH = 7.5–8.0,
80 mM NaCl, and 5 mM MgCl2, 1 mM TCEP) in the pres-
ence and absence of DR4 TRE DNA were recorded using
a JASCO J-815 CD spectrometer. Protein to DNA ratio
was 1: 1.1 for all experiments. All spectra were collected at
100 nmmin1 scan rate in 2 mm cuvettes maintained at
4 °C. The band width was 4 nm with data pitch 1 nm. CD
spectra of buffer and DR4 TRE (4–5 lM) were also
recorded separately as controls. Each spectrum shown is
the result of 30 spectra accumulations, averaged and
smoothed. All the spectra were corrected for the contribu-
tions of the buffer and TRE DR4 [47]. Mean residue ellip-
ticity ([h], (deg cm2 dmol1) was calculated using the CAPITO
software [48].
Results
Here, we present data from studies on a 154-amino
acid, two-domain molecular construct that encom-
passes the contiguous A/B (N terminus) and the C
domains (DBD) of TRa (Fig. 1A). The TRa A/B
domain comprises approximately 50 amino acids with
an evolutionary conserved KRKRK motif (Fig. 1B)
consisting of multiple charged residues [21,24]. Addi-
tionally, this construct contains a single tryptophan
residue that is conveniently located within the A/B
domain (19Trp) and adjacent to the KRKRK motif
which has enabled us to monitor the local changes in
conformation with steady-state intrinsic tryptophan
fluorescence spectroscopy. In summary, we present
data on the structural conformation of the TRa A/B
domain, the conformational changes in this domain
that are transmitted by allostery when the DBD (C
domain) binds DNA, and the effect of the A/B
domain on DNA recognition and binding.
The structural topology of TRa is shown in Fig. 1A.
The two TRa constructs – TRa (A/B + DBD) and
TRa (DBD), were purified to homogeneity as mono-
mers of TR (A/B + DBD; 20.1 kDa) and TR (DBD;
15.9 kDa; Fig. 1C,D).
The TRa A/B ↔ DBD allostery influences the
binding affinity for DNA
The selectivity for DNA is central to the transcriptional
activity of NRs. Here, we provide evidence that allostery
between the TRa A/B domain and the DBD also occurs
in reverse, i.e. TRa A/B domain can influence the beha-
viour of the TRa (C domain only) vis-a-vis its DNA-
binding affinity. Using ITC, we compare the binding
affinity (Kd) of TRa (A/B + DBD) domains and TRa
(DBD) for DR4 TRE DNA. We observe a three-fold
increase in affinity of the intact TRa (A/B + DBD)
domain for DR4 TRE DNA (Kd = 2.31  0.21 lM)
over the truncated TRa DBD (Kd = 6.65  0.50 lM;
Fig. 2). Also, the stoichiometry (N) of binding by both
TRa (A/B + DBD) and TRa (DBD) is approximately
N = 0.5 for TRE DR4, indicating that a single DR4
TRE binds two protein molecules. This is consistent
with previous data showing two TR-interacting half-
sites within the DR4 TRE [32,45]. Analyses of the ther-
modynamic parameters suggest that the TRa (A/
B + DBD) ↔ DR4 TRE interaction is entropically less
favourable (TDS = 2.05 kcal/mol) than the corre-
sponding entropic contributions to the TRa (DBD) ↔
DR4 TRE interactions (TDS = 1.08 kcalmol1). There-
fore, it is likely that the higher affinity between TRa (A/
B + DBD) and DR4 TRE is directed by the approxi-
mately 1.6-fold higher enthalpic contribution
(ΔH = 9.63  1.20 kcalmol1) over the correspond-
ing TRa (DBD) ↔ DR4 TRE interactions
(ΔH = 5.98  0.43 kcalmol1; Table 1).
TRE binding to the DBD can influence specific
local conformation of the A/B domain
Our studies above indicate that there is an allosteric
pathway that links the DNA-binding site within the
TRa DBD to the N-terminal TRa A/B domain
(Fig. 2). Here, we sought to determine if the DNA-
dependent allosteric communication between TRa A/
B ↔ DBD is manifested in measurable conforma-
tional changes, specifically within the TRa A/B
domain. Fortuitously, there exists only a single Trp
residue within the entire TRa (A/B + DBD) molecu-
lar construct. Furthermore, at position 19 this 19Trp
is also both midway within the TRa A/B domain
(residues 1–50) and distal from the DNA-binding
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TRa DBD (residues 51–154; Fig. 1B). Thus, this sin-
gle Trp enables us to directly identify conformational
changes within the central region of TRa (A/
B + DBD). Trp fluorescence quenching has been a
common indicator of local and global conformational
changes within the NR A/B domains [35,49,50] and
Fig. 2. ITC measurements were performed to measure heat changes upon titrating DR4 TRE DNA into (A). TRa (A/B + DBD) and (B). TRa
(DBD). For all titrations, the c values (c = nKaMtot, where n is the stoichiometry parameter, Ka is the association constant = 1/Kd and Mtot is
the concentration of the macromolecule, TRa) range from 6.5 to 9, which is within the ideal range for determining binding constants by ITC
[73]. Data obtained are summarized in Table 1.
Table 1. Thermodynamic parameters of TRE DR4 interaction with TRa (A/B + DBD) and TRa DBD. Parameters are determined at 25 °C and
pH = 7.5, as described in Experimental Procedures. The reported values are the average of three experiments and the errors are the
standard deviation.
Protein complexes Kd (lM) ΔH (kcalMol1) N a ΔG (kcalMol1) TΔS (kcalMol1)
TRa (A/B + DBD) + DR4 2.31  0.21 9.63  1.20 0.54  0.03 7.68 2.05
TRa (DBD) + DR4 6.65  0.50 5.98  0.43 0.53  0.02 7.06 1.08
a The apparent stoichiometry from the curve fitting data.
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due to allostery [16]. We monitored the dose-depen-
dent changes in intrinsic steady-state tryptophan
fluorescence, accompanied by an approximately 5 nm
red-shift in fluorescence maxima, within TRa (A/
B + DBD) in the presence of DR4 TRE (Fig. 3A).
The measurable decrease in fluorescence suggests a
specific change in the 19Trp conformation, and fur-
thermore, the conformational changes within the
19Trp sidechain are more likely from a progressive
decrease in its local hydrophobic environment, pre-
sumably from an increased exposure to the surround-
ing buffer [16]. These titrations were also analysed to
provide a quantitative measure of binding affinity:
since the two DR4 half-sites are indistinguishable for
binding TRa [32], the average binding affinity of TRa
(A/B + DBD) for DR4 TRE is Kd = 2.69  0.22 lM.
This binding constant confirms data obtained by
calorimetry.
TRE binding to the DBD results in unfolding of
the TRa A/B domain
The spectroscopic analyses above suggest an allosteric
conformational change within the TRa A/B domain
upon binding DNA at the TRa(DBD). To determine
the specific DNA-dependent changes in structure
within the TRa A/B domain, we utilized CD spec-
troscopy. Given that minor changes in the secondary
structure of proteins can be detected in the raw CD
spectra (h in rad cm1 vs. wavelength in nm) in the
far-UV (k = 190–260 nm) range, we compared the CD
spectra of the TRa (A/B + DBD) domains with TRa
(DBD) in the absence and when complexed with DR4
TRE (Fig. 3B). For the TRa (DBD), there is a promi-
nent change in the minima at 208 nm and 222 nm of
the CD spectrum in the presence of DNA, which sug-
gests a significant increase in a-helical structure of the
Fig. 3. Conformational changes determined by Fluorescence and CD spectroscopy. (A) Change in intrinsic tryptophan fluorescence of TRa
(A/B + DBD) is monitored in response to increasing levels of DR4 TRE DNA. The data above are obtained after subtracting buffer and DR4
TRE DNA contributions. In addition, no static quenching of molecular Trp was observed by DR4 TRE DNA. (B and C) Raw CD spectra of
TRa (A/B + DBD) and TRa (DBD), respectively,  DR4 TRE DNA. (D) The CD ([h], (deg cm2 dmol1) vs. wavelength, nm) spectra of the TRa
(A/B domain) was calculated by individually subtracting the [h] values for TRa (DBD) from TRa (A/B + DBD), for each corresponding
wavelength,  DR4 TRE DNA, respectively. The assumption made is that the conformations of the TRa (C domain),  DR4 TRE DNA, are
the same in both TRa (A/B + DBD) and TRa (DBD). Inset, CD spectra of TRa (A/B domain) measured directly  DR4 TRE.
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TR(DBD) upon binding DNA (Fig. 3C). Such confor-
mational changes in NR DBDs have been previously
observed using NMR spectroscopy confirming a
dosage-dependent stabilization of the NR DBD upon
binding DNA [51–55]. In this study, the CD spectra of
TRa (A/B + DBD) indicates that while the TRa seg-
ment is predominantly a-helical, the complexation of
TRa (A/B + DBD) with DNA results in a markedly
smaller change in secondary structure from the DNA-
free protein when compared with the corresponding
structural changes within the TRa DBD-only
(Fig. 3C). To determine the source of this discrepancy
between the TRa (A/B + DBD) and TRa DBD, we
subtracted the spectroscopically measured molar ellip-
ticity of CD of the TRa(DBD) from the TRa (A/
B + DBD) domain. The resulting spectrum estimates
the ‘calculated’ molar ellipticity ([h], (deg cm2 dmol1),
and therefore the conformational change, of the TRa
(A/B domain) within the TRa (A/B + DBD):DNA
complex (Fig. 3D). Additionally, we do not detect sig-
nificant secondary structure changes to the isolated
TRa (A/B domain) in the presence of DR4 TRE
(Fig. 3D inset). Taken together, these results suggest
that the TRa (A/B domain) has partial a-helical sec-
ondary structure within the ‘DNA-free’ TRa (A/
B + DBD). Upon binding DNA, the contiguous A/B
domain and the DBD undergo contrasting conforma-
tional changes – while the A/B domain appears to con-
vert from a more structured to a conformationally
less-rigid state, the DBD becomes conformationally
more stable. Overall, this a-helical-to-random coil
unfolding of the TRa A/B domain appears to counter-
act the propensity for greater a-helicity within the
TRa(DBD) upon binding DR4 TRE. This may
explain, in part, the smaller overall change in TRa (A/
B + DBD) in comparison with the TRa(DBD), upon
binding DR4 TRE.
Discussion
Multiple lines of evidence suggest that the NR A/B
domains are flexible and can adopt distinct conforma-
tions through allostery initiated by DNA:DBD interac-
tions [12,34,43,49,50,56–59]. A common observation is
that the A/B domains in all NRs studied to date, the
DNA-initiated allostery elicits an increase in secondary
structure (mostly a-helicity) of this domain.
Multiple attempts to determine the structures of
full-length NRs have failed to identify the conforma-
tion of their N-terminal domains [60]. Yet, all these
structures have indicated that there is no apparent
direct interaction between the A/B domain and the
DBD. Our observations suggest that DNA-dependent
conformational changes within the TRa A/B domain
are distinct from the corresponding changes within
the other NR A/B domains listed above. The implica-
tions for the unique mode of TRa A/B domain ↔
DBD allostery are broad. For instance, the TRa A/B
domain is reported to interact with several cellular
cofactors including TFIIB [21–24] and TBP [25]. Sim-
ilar interactions have been observed between NRs
and the PIC, such as the androgen (AR) [61,62],
COUP-TF [63], oestrogen (ER) [63,64], GR [65], min-
eralocorticoid (MR) [66] and PR [34,63] receptors,
among others. In each of these NRs, and distinct
from TRa as reported here, the A/B domain is con-
strained to a more folded conformation by DNA-
allostery. This more-structurally constrained A/B
domain is observed to enhance the NR↔cofactor
interaction.
In TRa, the sequence of basic residues 23KRKR27K
has been identified to make specific interactions with
TFIIB (Fig. 1B) [24]). Adjacent to this basic motif is
19Trp, which we show here by DR4 TRE DNA dose-
dependent fluorescence quenching to undergo confor-
mational changes to a more exposed environment and
this would be expected with the unfolding of this
region of the TRa A/B domain. From truncation and
associated binding studies, the corresponding TRa-
interacting domain of TFIIB is identified to be con-
tained within residues 178–201 of an amphipathic a-
helix [24]. Curiously, this TRa-interacting TFIIB a-
helix has also separately been identified as integral to
the binding interface between TFIIB and DNA [67].
Together, these studies suggest that the formation of
the TRa:TFIIB and the TFIIB:DNA complexes are
mutually exclusive and that binding to TRa can dis-
rupt the TFIIB-DNA complex. In the absence of
direct structural data, it is tempting to speculate that
the DNA-induced unfolding of the TRa A/B domain
plays a role in inserting itself into the TFIIB-DNA
complex and the newly created TRa:TFIIB is stabi-
lized by both interactions made by the charged
23KRKR27K and through the exposed apolar back-
bone of the TRa A/B domain. Indeed, such DNA-
induced unfolding events are less commonly reported
in the literature and the Ets-1 transcription factor is a
singular prior example of an analogous DNA-induced
unfolding within a flanking domain through allostery
[68,69]. In Ets-1, this induced unfolding is proposed to
ameliorate inhibitory intramolecular interactions and
encourage intermolecular interactions that promote
gene transcription.
Additionally, this study reinforces the observation
that DNA recognition is finely tuned by the domains
flanking the NR DBD. In both DNA-bound TRa:
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RXR heterodimeric [45] and the TRb monomeric [46]
structures, the conformation of the TR DBD is virtu-
ally identical, suggesting a generic mechanism for
DNA recognition and binding. Yet, using DBD and
DBD-LBD constructs of TRa, we have earlier estab-
lished that the affinity of the DBD for DNA can be
modulated through intramolecular allostery [32].
Moreover, even subtle changes within these flanking
domains (A/B or E/F domains) such as mutations [70]
and interactions with cellular factors [32] or small-
molecule ligands [71] can affect DNA binding. Given
the distinct unfolding process of the TRa A/B domain,
the mechanism by which this domain can allosterically
influence DBD↔DNA interactions is likely to be dif-
ferent from those of AR [35] and PR [72].
In summary, our data here suggest a distinct conse-
quence of allostery within TRa. The data from CD
spectroscopy show that conformational changes
induced within the TR(DBD) are transmitted ‘up-
stream’ to the flanking A/B domain. The resultant
conformation of the TRa A/B domain is less ordered
within the intact, DNA-bound TRa (A/B + DBD)
than in the absence of DNA. This unfolding results in
the repositioning of 19Trp observed from the quench-
ing of tryptophan fluorescence. The unusual feature of
DNA-induced, allosterically driven conformational
changes within the TRa A/B domain is the overall loss
in secondary structure, quantified as a decrease in its
a-helicity. Finally, this study showcases the diversity in
the structural response to allostery within the NR
superfamily. We are drawn to hypothesize that such
structural responses have been evolutionarily selected
to optimize the specific behaviour of individual mem-
bers of these NR transcription factors.
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